Cogent Biosciences (NASDAQ:COGT - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect Cogent Biosciences to post earnings of ($0.55) per share for the quarter.
Cogent Biosciences Price Performance
Shares of COGT opened at $4.91 on Tuesday. The firm has a 50 day simple moving average of $6.04 and a two-hundred day simple moving average of $8.12. Cogent Biosciences has a one year low of $3.72 and a one year high of $12.61. The company has a market cap of $558.58 million, a P/E ratio of -1.98 and a beta of 1.67.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on the stock. Needham & Company LLC reissued a "hold" rating on shares of Cogent Biosciences in a research report on Wednesday, February 26th. Piper Sandler raised shares of Cogent Biosciences to a "strong-buy" rating in a research report on Friday, March 7th. HC Wainwright reduced their target price on Cogent Biosciences from $17.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday, January 14th. Scotiabank assumed coverage on Cogent Biosciences in a report on Friday, March 7th. They set a "sector outperform" rating and a $17.00 price target on the stock. Finally, Robert W. Baird cut their price objective on Cogent Biosciences from $10.00 to $8.00 and set a "neutral" rating on the stock in a research report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Cogent Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $14.43.
Read Our Latest Analysis on Cogent Biosciences
About Cogent Biosciences
(
Get Free Report)
Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cogent Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cogent Biosciences wasn't on the list.
While Cogent Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
